Surgical treatment for hepatocellular carcinoma in cirrhotic patients. Guide to the selection and decision-making process in a context of multimodal strategy

Clinical and Translational Oncology

Volumn 11, Issue 1, 2009, Pages 20-27

  González, Héctor Daniel ^a   Figueras, Joan ^a  

^a Hospital Trueta   (Spain)

Author keywords

Hepatocellular carcinoma; Human; Liver carcinoma; Primary liver tumours; Surgery; Surgical

Indexed keywords

ACYCLIC RETINOID; LAMIVUDINE; PEGINTERFERON; PI 88; PLACEBO; RAS PROTEIN; RETINOID DERIVATIVE; RIBAVIRIN; SORAFENIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADVANCED CANCER; AGE DISTRIBUTION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASCITES; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL DECISION MAKING; CLINICAL TRIAL; DRUG TARGETING; GRAFT SALVAGE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MULTIMODALITY CANCER THERAPY; NAUSEA; OVERALL SURVIVAL; PATIENT SAFETY; PATIENT SELECTION; PROGNOSIS; SURVIVAL TIME; TREATMENT CONTRAINDICATION; VOMITING; ABDOMINAL SURGERY; LIVER TUMOR; METHODOLOGY; MORTALITY; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION;

EID: 65349180981     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-009-0306-1     Document Type: Article

References (48)

1. Fan ST, Lai EC, Lo CM et al (1995) Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis. Arch Surg 130:198-203
2. Figueras J, Jaurrieta E, Valls C et al (2000) Resection or transplantation for hepatocellular carcinoma en cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg 190:580-587
3. Figueras J, Jaurrieta E, Valls C et al (1997) Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: A comparative study. Hepatology 25:1485-1489
4. Figueras J, Ibañez L, Ramos E et al (2002) La resección es un buen tratamiento del hepatocarcinoma sobre el hígado cirrótico en pacientes seleccionados. Cir Esp 71:28-33
5. Fuster J, Garcia-Valdecasas J, Grande L et al (1996) Hepatocellular carcinoma and cirrhosis. Results of surgical treatment in a European series. Ann Surg 223:297-302
6. Margarit C, Escartín A, Castells Ll et al (2005) Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh Class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl 11:1241-1251
7. Yamamoto J, Iwatsuki S, Kosuge T et al (1999) Should hepatomas be treated with hepatic resection or transplantation? Cancer 86:1151-1158
8. Llovet J, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37:429-442
9. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208-1236
10. Llovet J, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907-1917
11. Figueras J, Valls C, Pamies J et al (1993) La quimioembolización en el tratamiento del hepatocarcinoma. Rev Esp Enf Digest 83:21-25
12. Varela M, Real M, Burrel M et al (2007) Chemoembolization of the hepatocellular carcinoma with drug-eluting beads: Efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474-481
13. Poon R, Fan S, Tsang F et al (2002) Locoregional therapies for hepatocellular carcinoma: A critical review from the surgeon's perspective. Ann Surg 235:466-486
14. Ferrero A, Vigano L, Polastri R et al (2005) Hepatectomy as treatment of choice for hepatocellular carcinoma in elderly cirrhotic patients. World J Surg 29:1101-1105
15. Makuuchi M, Kosuge T, Takayama T et al (1993) Surgery for small liver cancers. Semin Surg Oncol 9:298-304
16. Bruix J, Llovet J (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35:519-524
17. Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 334:693-699
18. Figueras J, Ibañez L, Ramos E et al (2001) Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: Results of a multicenter study. Liver Transpl 7:877-883
19. Volk M, Vijan S, Marrero J (2008) A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transpl 8:839-846
20. Roayaie S, Llovet J (2005) Liver transplantation for hepatocellular carcinoma: Is expansion of criteria justified? Clin Liver Dis 9:315-328
21. Yao F, Ferrell L, Bass N et al (2001) Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 33:1394-1403
22. Roayaie S, Frischer J, Emre S et al (2002) Longterm results with multimodal adjuvant therapy and liver transplantation for the treatment of HCC larger than 5 centimeters. Ann Surg 235:533-539
23. Fernandez J, Robles R, Marin C et al (2003) Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size? Transplant Proc 35:1818-1820
24. Duffy J, Vardanian A, Benjamin E et al (2007) Liver transplantation criteria for hepatocellular carcinoma should be expanded. A 22-year experience with 467 patients at UCLA. Ann Surg 246:502-511
25. Belghiti J, Carr I, Greig P et al (2008) Treatment before liver transplantation for HCC. Ann Surg Oncol 15:993-1000
26. Fong Y, Sun R, Jarnagin W et al (1999) An analysis of 412 cases of hepatocellular carcinoma at a western center. Ann Surg 229:790-800
27. Wayne J, Lauwers G, Ikai I et al (2002) Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg 235:722-731
28. Bilimoria M, Lauwers G, Doherty D et al (2001) Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg 136:528-535
29. Tsai T, Chau G, Lui W et al (2000) Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 127:603-608
30. Vauthey J, Lauwers G, Esnaola N et al (2002) Sim plified staging for hepatocellular carcinoma. J Clin Oncol 20:1527-1536
31. Esnaola N, Lauwers G, Mirza N et al (2002) Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg 6:224-232
32. Vauthey J, Ribero D, Abdalla E et al (2007) Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment. J Am Coll Surg 204:1016-1028
33. Llovet J, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329-338
34. Sala M, Forner A, Varela M et al (2005) Prognostic prediction in patients with hepatocellular carcinoma. Semin Liver Dis 25:171-180
35. Llovet J, Di Bisceglie A, Bruix J et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698-711
36. Yoo H, Patt C, Geschwind J et al (2003) The outcome of liver transplantation in patients with hepatocellular carcinoma in the US between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 21:4329-4335
37. Poon R, Fan S, Lo C et al (2002) Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: Implications for a strategy of salvage transplantation. Ann Surg 235:373-382
38. Yea S, Narla G, Zhao X et al (2008) Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology 134:1521-1531
39. Pang R, Poon R (2007) From molecular biology to targeted therapies for hepatocellular carcinoma: The future is now. Oncology 72:30-44
40. Bruix J, Hessheimer A, Forner A et al (2006) New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 25:3848-3856
41. Llovet J (2007) Clinical and molecular classification of hepatocellular carcinoma. Liver Transpl 13[11 Suppl 2]:13-16
42. Llovet JM, Ricci S, Mazzaferro V et al (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 24:378-390
43. Mendez-Sanchez N, Vasquez-Fernandez F, Zamora-Valdes D et al (2008) Sorafenib, a systemic therapy for hepatocellular carcinoma. Ann Hepatol 7:46-51
44. Muto Y, Moriwaki H, Ninomiya M et al (1996) Prevention of second primary tumors by an acyclic retinoid, polypremoic acid, in patients with hepatocellular carcinoma: Hepatoma Prevention Study Group. N Engl J Med 334:1561-1567
45. Lau W, Leung T, Ho S et al (1999) Adjuvant intraarterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: A prospective randomised trial. Lancet 353:797-801
46. Boucher E, Corbinais S, Rolland Y et al (2003) Adjuvant intra-arterial injection of iodine-131-labelled lipiodol after resection of hepatocellular carcinoma. Hepatology 38:1237-1241
47. Clavien P (2007) Interferon. The magic bullet to prevent hepatocellular carcinoma recurrence after resection? Ann Surg 245:843-845
48. Garner J, Homber J (2007) The interactive effect of prognostic factors and PI-88 use on the delay of hepatocellular carcinoma (HCC) recurrence following curative partial hepatic resection. Program and abstracts of the 58th Annual Meeting of the American Association for the Study of Liver Diseases. November 2-6, Boston, Massachusetts. Abstract 405